Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haleon’s separation from GSK created a consumer-health giant with dozens of power brands—and a web of disclosures that can overwhelm even seasoned analysts. Sales are broken out across oral care, pain relief, vitamins and more, while its first standalone Form 20-F runs hundreds of IFRS-heavy pages. If you have ever asked, "Where do I find Haleon insider trading Form 4 transactions" or "How do I decode Haleon’s quarterly earnings report 10-Q filing?", you know the challenge.
Stock Titan solves it. Our AI reads every new filing the moment it hits EDGAR, then delivers plain-English summaries, red-flags and searchable key terms. Whether you need Haleon Form 4 insider transactions in real-time, a side-by-side view of segment revenue from the latest 6-K, or want Haleon SEC filings explained simply, the platform highlights what matters: advertising spend trends, litigation provisions, post-spin debt covenants and more. Long-tail queries such as "Haleon executive stock transactions Form 4", "understanding Haleon SEC documents with AI", or "Haleon earnings report filing analysis" resolve to the exact section—no scrolling required.
All filing types are here, updated continuously: the Haleon annual report 10-K simplified (20-F), Haleon proxy statement executive compensation, and every Haleon 8-K material events explained. Use our tools to:
- Track insider buying and selling before marketing launches
- Compare vitamin and mineral supplement growth quarter-over-quarter
- Spot supply-chain disclosures in material event filings
On 11 July 2025, Haleon plc (LSE/NYSE: HLN) disclosed a TR-1 major shareholding notification from Wellington Management Group LLP. The investment manager’s aggregated interest fell from 5.87 % to 5.29 % of Haleon’s voting rights as of 10 July 2025, comprising 4.97 % held directly through ordinary shares (446.9 m votes) and 0.32 % via financial instruments (predominantly depository receipts and small equity swaps). The absolute position equals 475.6 m voting rights.
The reduction keeps Wellington above the critical UK 5 % disclosure threshold but signals incremental selling. No operational or earnings data are included; the filing is purely ownership-related.
Haleon plc (NYSE/LSE: HLN) has released unaudited historic pro-forma financials that restate 2023-2025 revenue under a new six-category reporting framework. The change, first signalled at the 1 May 2025 Capital Markets Day, splits the former “Digestive Health & Other” segment into two lines—Digestive Health and Therapeutic Skin Health & Other—and moves the Smokers Health franchise into Respiratory Health. Beginning with the Half-Year results on 31 July 2025, Haleon will report:
- Oral Health
- Vitamins, Minerals & Supplements (VMS)
- Pain Relief
- Respiratory Health
- Digestive Health
- Therapeutic Skin Health & Other
Key restated figures (FY 2024 vs FY 2023):
- Total revenue £11.23 bn, down 0.6%; organic revenue growth +5.0%
- Oral Health £3.31 bn (+5.6% reported, +9.6% organic) – strongest absolute contributor
- VMS £1.70 bn (+3.4% reported, +7.6% organic) – solid rebound from 0.9% organic in 2023
- Pain Relief £2.56 bn (-3.3% reported, +0.1% organic) – softness after 7.4% organic in 2023
- Respiratory Health £2.12 bn (-5.4% reported, +1.0% organic) – lapping strong 2023 cold/flu season
- Digestive Health £1.03 bn (+1.7% reported, +5.5% organic)
- Therapeutic Skin Health & Other £0.51 bn (-17.5% reported, +9.8% organic) – large FX/disposal drag
Q1 2025 restated revenue shows modest momentum: total £2.85 bn (-2.3% reported, +3.5% organic) with Oral Health (+3.0% reported) and Pain Relief (-0.2% reported, +2.6% organic) leading. Geographical splits are unchanged and no guidance is updated in this filing.
The recast enhances transparency around category-level trends and is intended to align external reporting with strategic growth priorities ahead of Haleon’s first standalone medium-term targets expected at H1 results.
Haleon plc (LSE/NYSE: HLN) filed a Form 6-K reporting progress on the share buyback programme announced 28 March 2025.
Daily trade: on 25 June 2025 the company repurchased 1,006,111 ordinary shares at a volume-weighted average price of 383.38 pence (high 384.80 p, low 380.70 p). All shares will be cancelled.
Completion of first tranche: Haleon has now finished the programme’s first tranche, acquiring 51,036,522 shares for an aggregate consideration of about £200 million. The tranche equates to roughly 0.6 % of the current share base.
Updated share capital: issued share capital is 8,988,533,553 shares of £0.01 each. After deducting 4,080,205 treasury shares, voting shares total 8,984,453,348. Investors should use this figure for FCA disclosure-threshold calculations.
Next steps: management will announce any further tranches separately. The filing contains no earnings, guidance, or operational updates.
FAQ
What is the current stock price of Haleon (HLN)?
What is the market cap of Haleon (HLN)?
